The importance of MRI in dementia diagnosis is already widely recognised, with structural imaging recommended to be used generally in the assessment of people with suspected dementia and also for the differentiation between AD and vascular dementia. 

The value of quantitative measurements obtained from structural MRI in identifying patients with early dementia has been recognised by two major consensus processes:

(i) the qualification of low hippocampal volume for the enrichment of clinical trials of early AD, and

(ii) recommendations for new diagnostic criteria stating that quantitative MRI can add confidence to timely diagnosis in AD

Atrophy in the hippocampus and other medial temporal lobe structures are the most widely used dementia biomarkers from structural MRI. An assessment of white matter hyperintensities (WMH), microbleeds and white matter lacunes is commonly performed to differentiate vascular dementia from other types of dementia.

Assessa enables a quantitative assessment of such biomarkers in clinical practice, and healthcare professionals can access technology that has already been proven to work in global clinical trial settings. Additional information about neuro-degeneration from structural MRI can add confidence to clinical diagnosis, resulting in a more rapid and accurate diagnosis and fewer inconclusive repeat visits to memory clinics. 

Download our white paper "Confident and Accurate Dementia Diagnosis with Assessa®" here.

See more